Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to ...
Study met the primary endpoint and all secondary endpoints, highly consistent with rapid response from the INTEGUMENT-1 and INTEGUMENT-2 pivotal trials For the primary endpoint, 25.4% of children ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Full data results will be presented at future medical conferences and in peer-reviewed journals. The INTEGUMENT-1 study met the primary endpoint and all secondary endpoints. Topline results were ...
Arcutis Biotherapeutics has announced promising results from its Phase 3 INTEGUMENT-OLE study concerning the investigational ZORYVE cream for treating atopic dermatitis (AD). The long-term study ...
Once-daily roflumilast cream at 0.15% improved symptoms of atopic dermatitis (AD) across multiple end points. According to investigators of the phase 3 studies that uncovered the findings, roflumilast ...
(NASDAQ:ARQT) is one of the overlooked growth stocks to buy now. On March 28, Arcutis Biotherapeutics presented new Phase 2 ...
Arcutis Biotherapeutics (ARQT) announced the enrollment of the last subject in the INTEGUMENT-INFANT Phase 2 open-label clinical study, which is evaluating the safety and tolerability of ...
Today, the FDA approved roflumilast cream 0.15% (Zorvye; Arcutis Biotherapeutics) for the treatment of mild to moderate atopic dermatitis in patients 6 years and older. Roflumilast cream 0.15% is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results